लोड हो रहा है...
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...
में बचाया:
| में प्रकाशित: | J Clin Med |
|---|---|
| मुख्य लेखकों: | , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
MDPI
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7564568/ https://ncbi.nlm.nih.gov/pubmed/32911840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092905 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|